$5.70
-0.05-0.87%
At close: -
$5.80
0.11.75%
After Hours: Nov 22, 7:59 PM EDT
Comments
Loading...
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock, Earnings Estimates, EPS, And Revenue
Recursion Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Feb 25
EPS Estimate
$-0.470
Quarterly Revenue Estimate
$14.6M
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$64.6M
Analyze the earnings history of Recursion Pharmaceuticals using advanced sorting and filters.
Data brought to you by Benzinga APIs
Recursion Pharmaceuticals (RXRX) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-06 | $-0.34 | $-0.35 | 2.86 % |
| Jun 2024 | 2024-08-08 | $-0.40 | $-0.40 | 0.00 % |
| Mar 2024 | 2024-05-09 | $-0.39 | $-0.42 | 7.14 % |
| Dec 2023 | 2024-02-27 | $-0.42 | $-0.45 | 6.67 % |
Recursion Pharmaceuticals (RXRX) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-06 | $26.08M | $29.84M | -12.6 % |
| Jun 2024 | 2024-08-08 | $14.42M | $13.75M | 4.85 % |
| Mar 2024 | 2024-05-09 | $13.49M | $12.65M | 6.65 % |
| Dec 2023 | 2024-02-27 | $10.89M | $20.53M | -46.9 % |
FAQ
When is Recursion Pharmaceuticals (NASDAQ:RXRX) reporting earnings?
Recursion Pharmaceuticals (RXRX) is scheduled to report earnings on February 25, 2025. The last reported earnings were for reported on November 6, 2024 for Q3.
What were the latest earnings per share (EPS) for Recursion Pharmaceuticals (NASDAQ:RXRX)?
The Actual EPS was $-0.34, which beat the estimate of $-0.35.
What were Recursion Pharmaceuticals’s (NASDAQ:RXRX) revenues?
The Actual Revenue was $26.1M, which missed the estimate of $29.8M.
Browse earnings estimates, EPS, and revenue on all stocks.